

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

PROFIT WARNING

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2024 (“**FY2024**”) and the information currently available to the Board, the Group is expected to record a net loss in a range of HK\$50 million to HK\$60 million for the FY2024 as compared to the net profit of approximately HK\$6 million for the year ended 31 December 2023 (“**FY2023**”). The Group’s loss attributable to owners of the Company of approximately HK\$46 million to HK\$56 million for the FY2024 as compared to profit attributable to owners of the Company of approximately HK\$7.5 million for the FY2023. Such changes for the FY2024 are mainly due to a one-off gain on disposal of subsidiaries of approximately HK\$69 million recorded for the FY2023.

The Company is still in the process of finalising the annual results of the Group for the FY2024. The information contained in this announcement is only based on the unaudited consolidated management accounts of the Group for the FY2024 and the information currently available to the Group, which have not been audited or reviewed by the auditors of the Company, nor reviewed by the audit committee of the Company. Details of the financial results of the Group will be disclosed in the Group’s annual results announcement for the FY2024 which will be published in due course pursuant to the requirements of the Listing Rules. Shareholders and potential investors are advised to read the financial results announcement carefully when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Kaisa Health Group Holdings Limited
Kwok Ying Shing
Chairman

Hong Kong, 17 March 2025

As at the date of this announcement, the Board comprises Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Mr. Liu Lihao, Ms. Luo Tingting, Mr. Xie Binhong and Mr. Yu Huiming as executive Directors; and Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying as independent non-executive Directors.